Quick answer
The point at which weight loss slows or stops despite continued GLP-1 therapy. Most patients plateau between 12-18 months on the same dose.
Full definition
A weight-loss plateau is a sustained period during which weight stops decreasing despite ongoing GLP-1 therapy and stable dose. Clinical trial data show mean weight loss continues for 12-18 months on Wegovy and Zepbound, then stabilizes. Plateaus reflect a new energy balance equilibrium — reduced fat mass means lower resting energy expenditure, and behavioral compensation may also occur. Strategies include dose optimization (if not already at max), reinforcing dietary and exercise behaviors, evaluating sleep and stress, and considering combination therapy. Plateaus do not necessarily mean treatment failure.
Deep dive
Weight-Loss Plateau: complete reference
A weight loss plateau на GLP-1 therapy is a period of weeks-to-months where weight loss stops despite continued treatment. Three common plateau windows: (1) Early plateau around weeks 8-12 during dose titration — body adapting to current dose, usually resolves with next dose escalation; (2) Mid-treatment plateau around months 6-9 — body reaching new metabolic equilibrium; (3) Final plateau around weeks 60-68 — STEP-1 trial showed most weight loss achieved by this point. Final plateau is not failure но the destination — body has reached a new defended set-point. Strategies для breaking plateaus: increase dose if not at maximum, ensure protein intake adequate, evaluate liquid calorie intake (often the culprit), increase resistance training, address sleep/stress, consider switching molecule classes (semaglutide → tirzepatide). Some plateaus simply reflect achievement of personal maximum response — not all patients reach trial-averaged 15% loss. Setting realistic expectations (5-25% individual range) prevents frustration.
- In practice
- You lose 1-2 lbs/week для 8 weeks on Wegovy, then suddenly stop losing for 3 weeks. That's often a normal mid-titration plateau — usually resolves with the next dose increase.
- Clinical context
- Three predictable plateau windows. Final plateau is the new equilibrium, not failure.
Medications
Weight-Loss Plateau is most directly relevant to the following GLP-1 medications:
Related terms
- Maintenance Dose — The target dose reached after titration, taken long-term for ongoing therapeutic effect. For Wegovy …
- Titration — The gradual dose escalation schedule used when starting GLP-1 therapy. Typically increases every 4 w…
- Weight Regain — The return of lost weight after stopping GLP-1 therapy. STEP 4 showed patients regained about two-th…
Continue learning
GLP1Zoom glossary is educational reference. Definitions are summary interpretations of clinical sources and not a substitute for prescribing-information detail. Full disclaimer.
References
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)